JP2015131856A5 - - Google Patents

Download PDF

Info

Publication number
JP2015131856A5
JP2015131856A5 JP2015086575A JP2015086575A JP2015131856A5 JP 2015131856 A5 JP2015131856 A5 JP 2015131856A5 JP 2015086575 A JP2015086575 A JP 2015086575A JP 2015086575 A JP2015086575 A JP 2015086575A JP 2015131856 A5 JP2015131856 A5 JP 2015131856A5
Authority
JP
Japan
Prior art keywords
alkyl
group
compound
cycloalkyl
replaced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015086575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015131856A (ja
JP6211032B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015131856A publication Critical patent/JP2015131856A/ja
Publication of JP2015131856A5 publication Critical patent/JP2015131856A5/ja
Application granted granted Critical
Publication of JP6211032B2 publication Critical patent/JP6211032B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015086575A 2009-09-25 2015-04-21 新規npr−bアゴニスト Expired - Fee Related JP6211032B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24596009P 2009-09-25 2009-09-25
US61/245,960 2009-09-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012531012A Division JP5893561B2 (ja) 2009-09-25 2010-09-23 新規npr−bアゴニスト

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017101128A Division JP2017137362A (ja) 2009-09-25 2017-05-22 新規npr−bアゴニスト

Publications (3)

Publication Number Publication Date
JP2015131856A JP2015131856A (ja) 2015-07-23
JP2015131856A5 true JP2015131856A5 (enExample) 2016-05-12
JP6211032B2 JP6211032B2 (ja) 2017-10-11

Family

ID=43781057

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012531012A Expired - Fee Related JP5893561B2 (ja) 2009-09-25 2010-09-23 新規npr−bアゴニスト
JP2015086575A Expired - Fee Related JP6211032B2 (ja) 2009-09-25 2015-04-21 新規npr−bアゴニスト
JP2017101128A Withdrawn JP2017137362A (ja) 2009-09-25 2017-05-22 新規npr−bアゴニスト

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012531012A Expired - Fee Related JP5893561B2 (ja) 2009-09-25 2010-09-23 新規npr−bアゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017101128A Withdrawn JP2017137362A (ja) 2009-09-25 2017-05-22 新規npr−bアゴニスト

Country Status (17)

Country Link
US (5) US8546523B2 (enExample)
EP (1) EP2480247B1 (enExample)
JP (3) JP5893561B2 (enExample)
KR (3) KR101768661B1 (enExample)
CN (2) CN105732767A (enExample)
AR (1) AR078445A1 (enExample)
AU (1) AU2010298256B2 (enExample)
BR (1) BR112012006579A2 (enExample)
CA (1) CA2773949C (enExample)
CL (2) CL2012000715A1 (enExample)
MX (3) MX2012003398A (enExample)
PH (1) PH12012500562A1 (enExample)
RU (3) RU2557290C2 (enExample)
TW (2) TWI577384B (enExample)
UY (1) UY32902A (enExample)
WO (1) WO2011038061A2 (enExample)
ZA (3) ZA201201630B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2510942T1 (sl) 2005-04-07 2016-01-29 Cardiorentis Ag Uporaba natriuretskega peptida za zdravljenje srčne odpovedi
WO2008014733A1 (de) * 2006-08-02 2008-02-07 Johannes Gutenberg-Universität Mainz Arzneimittel gegen lct-vergiftungen
BR112012006579A2 (pt) * 2009-09-25 2016-11-22 Alcon Res Ltd agonistas de npr-b.
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.
US20150045301A1 (en) * 2011-12-16 2015-02-12 Kalos Therapeutics, Inc. Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases
WO2014115033A2 (en) * 2013-01-25 2014-07-31 Cardiorentis Ltd. Methods of treating cardiovascular indications
CN109563144B (zh) 2016-06-01 2023-03-28 雅斯娜 化合物
JP2020505476A (ja) * 2017-02-01 2020-02-20 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 眼科障害の治療のための化合物および組成物
US20210121534A1 (en) * 2018-06-19 2021-04-29 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
CA3120196A1 (en) 2018-11-16 2020-05-22 Arcus Biosciences, Inc. Inhibitors of arg1 and/or arg2
KR20230024352A (ko) * 2020-06-12 2023-02-20 파마인 코포레이션 C형 나트륨이뇨 펩타이드 및 이의 급성 폐 손상의 치료에서의 방법
KR102677730B1 (ko) * 2023-03-27 2024-06-27 나인바이오팜 주식회사 지방 분해 효능을 갖는 펩타이드 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757048A (en) 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
AU2927889A (en) * 1987-12-24 1989-07-19 California Biotechnology, Inc. Linear analogs of atrial natriuretic peptides
AU4211989A (en) * 1988-08-18 1990-03-23 California Biotechnology, Inc. Atrial natriuretic peptide clearance inhibitors
EP1118329A4 (en) 1998-09-28 2004-12-15 Santen Pharmaceutical Co Ltd LACRYMAL SECRETION PROMOTERS OR OPHTHALMOLOGICAL DROPS CONTAINING NATRIURETIC PEPTIDES AS ACTIVE INGREDIENTS FOR TREATING KERATOCONJUNCTIVITY
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
ATE496060T1 (de) * 2004-07-15 2011-02-15 Univ Queensland Proteinartige verbindungen und anwendungen davon
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US20090035287A1 (en) * 2005-09-26 2009-02-05 Zurit Levine Atrial natriuretic peptide (anp) splice variants and methods of using same
EP1951277A2 (en) * 2005-10-14 2008-08-06 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins
KR101434612B1 (ko) 2006-03-30 2014-08-26 팔라틴 테크놀로지스 인코포레이티드 사이클릭 나트륨 이뇨 펩타이드 구조물
EP2004633A4 (en) * 2006-03-30 2009-08-26 Palatin Technologies Inc LINEAR NATRIURETIC PEPTIDE CONSTRUCTS
AR069409A1 (es) * 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
BR112012006579A2 (pt) * 2009-09-25 2016-11-22 Alcon Res Ltd agonistas de npr-b.
WO2011038066A2 (en) 2009-09-25 2011-03-31 Alcon Research, Ltd. Novel npr-b agonists
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.

Similar Documents

Publication Publication Date Title
JP2015131856A5 (enExample)
CR20210578A (es) Derivados de ácido itacónico y usos de estos en el tratamiento de una enfermedad inflamatoria asociada con una respuesta inmunotaria indeseable
UY37854A (es) Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos
WO2020083971A3 (en) New anthelmintic compounds
MX390903B (es) Composición y método para el crecimiento del cabello.
CN107995862B8 (zh) 包含sglt-2抑制剂之液态药物组合物
MX376106B (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infección por virus de hepatitis b.
MX421406B (es) Composiciones de acido ribonucleico de interferencia (arni) contra el virus de la hepatitis b (hbv) y metodos de uso de estas
MX390302B (es) Oxiesteroles y metodos de uso de los mismos
JP2016540749A5 (enExample)
WO2016044446A3 (en) Sgc stimulators
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
JP2016518437A5 (enExample)
JP2014221779A5 (enExample)
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
JP2016518328A5 (enExample)
MX2020010690A (es) Oxiesteroles y metodos de uso de los mismos.
JP2017514910A5 (enExample)
EP4316591A3 (en) Oxysterols and methods of use thereof
JP2018501215A5 (enExample)
ZA202409847B (en) Gastro-resistant controlled release oral dosage forms
JP2016540015A5 (enExample)
RU2018101431A (ru) Ингибиторы индоламин-2,3-диоксигеназы
MY197561A (en) Composition for increasing expression of pgc-1?
CN111526878A (zh) 含三萜类化合物的药物组合物及其用途